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Transcription infidelity (TI) is a mechanism that increases RNA and protein diversity. We found 
that single-base omissions (i.e., gaps) occurred at significantly higher rates in the RNA of highly-
allergenic legumes. Transcripts from peanut, soybean, sesame, and mite allergens contained a 
higher density of gaps than those of non-allergens. Allergen transcripts translate into proteins 
with a cationic carboxy-terminus depleted in hydrophobic residues. In mice, recombinant TI 
variants of the peanut allergen Ara h 2, but not the canonical allergen itself, induced, without 
adjuvant, the production of anaphylactogenic specific IgE (sIgE) binding to linear epitopes on 
both canonical and TI segments of the TI variants. The removal of cationic proteins from bovine 
lactoserum markedly reduced its capacity to induce sIgE. In peanut-allergic children, the sIgE 
reactivity was directed toward both canonical and TI segments of Ara h 2 variants. We 
discovered two previously-unreported peanut allergens because of their RNA-DNA divergence 
gap patterns and TI peptide amino-acid composition. Finally, we showed that the sIgE of 
children with IgE-negative milk allergy targeted cationic proteins in lactoserum. We propose that 
it is not the canonical allergens, but their TI variants, that initiate sIgE isotype switching, while 




Clinical allergy resulting from the inappropriate response of mammalian immune systems to 
otherwise harmless exogenous substances has become a significant public health concern in 
western countries (1, 2). The prevalence of food allergy in the USA is estimated to be 10.8 % 
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(3); that of peanut allergy doubled in the last decade to now affect 1.2-2% of children and 0.6-
0.8% of adults (4). Our current understanding of the molecular cascade of events leading to the 
development of allergic diseases remains limited (2). The immunoglobulin E (IgE) plays a 
central role in allergy (5), as this isotype is produced in response to a cytokine/chemokine pattern 
that defines the Th2 immune response (6). Allergens binding to IgE anchored to the FcεRI high-
affinity IgE receptors on mast cells and basophils cause their aggregation and trigger a signaling 
cascade leading to the release of potent pro-inflammatory mediators (7). 
 
To date, the intrinsic structures or patterns common to all allergenic proteins that are responsible 
for inducing a specific immunoglobulin E (sIgE) production remain unknown (2). 
We and others have shown that RNA sequences occasionally differ from their canonical DNA 
templates (8–16). These RNA-DNA divergences (RDD) occur during, or immediately after, 
transcription and are collectively referred to as transcription infidelity (TI) (15) or RNA editing 
(16); for a review, see (17). Transcription infidelity results from RNA Pol II errors, causing base 
substitutions within and across base families. Despite several regulatory mechanisms preventing 
the translation of erroneous messages (i.e., a nonsense-mediated decay (18)), RNAs carrying TI 
events are often translated (8, 13). 
 
Herein, we report what we believe is a novel RDD event: single-base omissions that create 
virtual RNA gaps causing translational frameshifts. As a result of such omissions, proteins 
translated from gapped RNAs contain two parts: 1) an amino-terminal segment whose sequence 
is the same as the canonical one, and 2) a different carboxy-terminal TI segment that, because of 
the degeneracy of the genetic code favoring basic amino acids, is cationic. The causal role of TI 
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variants in eliciting IgE production was established in mice using both recombinant TI variants 
of the major peanut allergen Ara h 2, as well as the purified, low-abundance, cationic fraction of 
bovine lactoserum. We then translated these findings from mice to humans in three different 
contexts. We identified two peanut allergens, which we believe to be novel, based on their RNA-
DNA divergence gap patterns and TI peptide amino-acid composition. We then showed that 
peanut-allergic patients have sIgE directed toward both canonical and TI segments of Ara h 2. 
Finally, we found that the serum IgE from "IgE-negative" milk-allergic children reacted with the 
low-abundance, cationic (that is TI variant-containing) rather than the anionic (i.e., TI variant-
depleted) fraction of bovine lactoserum. Altogether, these findings indicate that single-gap TI 






The RNA-DNA divergence gap rates correlate with the differential allergenicity of three 
legumes. We began by analyzing mismatches between the genomes and transcriptomes of three 
legumes: the highly allergenic peanut (Arachis hypogea), the moderately allergenic soybean 
(Glycine max), and the rarely allergenic green bean (Phaseolus vulgaris); see Supplementary 
material 1 for the bioinformatics method (19). We first calculated the RDD gap rates (i.e., the 
overall TI gap burden) following the method depicted in Figure 1A. With such calculation, we 
showed that A and T omissions were significantly more frequent in the peanut than in the 
soybean and rarest in the green bean, thus mirroring their allergenicity (Figure 1B). In the 
peanut, gaps affected more commonly A and T repeats (Figure 1C), and the RDD gap rate 
increased with the length of the repeats despite their decreasing frequency (solid line in Figure 
1C). In peanuts, when comparing the composition of bases flanking A and T gaps compared to 
those around As and Ts unaffected by transcription errors, we observed that the five-to-six bases 
surrounding gapped As and Ts appeared to influence the presence of the TI events (Figure 1D). 
The most influential bases were those downstream of As and upstream of Ts (see the 
Supplementary material 1 for the MEME analysis of DNA motifs observed at each specific gap 
position).   
 
Frameshifted RNAs translate into cationic peptides. The in silico translation of single-base 
omissions from peanut mRNA sequences showed a modest, but highly significant, increase in 
the percentage of basic amino acids (AAs) and a profound decrease in that of acidic AAs (Figure 
2A); these variations are consistent with the genetic code containing relatively more codons for 
basic than acidic AAs. When combined, these changes cause a two-to-three log increase in the 
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isoelectric point of the TI peptides translated from the sequence downstream of a gap (Figure 
2B). We then evaluated the impact of deleting each codon as a function of the first base of the 
next codon, assuming an equal probability for the four bases. Taking into account the peanut 
codon usage bias and the AA composition of the canonical proteins, we calculated the 
probabilities of gain, loss, or conservation of each AA (Table 1). Subsequently, we estimated the 
theoretical composition of peanut proteins translated from frameshifted RNA and found that 
more than 90% of both observed basic AA gains and acidic AA losses are explained by this 
simple calculation (Table 2). Therefore, because of the biased degeneracy of the genetic code 
that favors basic (i.e., positively-charged AAs), the consequence of frameshifts occurring at any 
given position and affecting any base is the potential translation of a cationic segment. The small 
difference in the predicted versus the observed upward shift in the isoelectric point is likely due 
to all bases not being equally affected by TI gaps, as shown above (Figure 1A). 
 
The RNA-DNA divergence gap patterns and the predicted AA composition of TI peptides are 
different in allergen versus non-allergen coding transcripts. To better understand the RDD gaps 
at the individual transcript level, we compared the RDD profiles in 11 of the 17 IUIS-recognized 
peanut allergens whose genomic sequences are sufficiently annotated with those of 10,224 
transcripts encoding peanut proteins not currently recognized as allergens (Table 3). We did not 
include six allergens in this analysis because of the high stringency constraints of our 
bioinformatics protocols: a perfect match to the respective DNA reference sequence was 
unavailable for Ara h 11, 12, 16 and 17, the position coverage was insufficient for Ara h 5, and 
Ara h 4 is, in fact, an isoform of Ara h 3 (20). 
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To summarize, we detected several essential differences between mRNAs coding for allergens 
and those translated into non-allergen proteins. The expression levels of peanut allergen-coding 
transcripts (ACTs) were significantly higher than those of non-allergen-coding transcripts 
(NACTs; Table 3). Allergen-coding transcripts encoded significantly smaller proteins and had a 
significantly higher gap rate compared to NACTs (Table 3). Finally, the AA composition of TI 
variants translated from gaps occurring in ACTs was significantly different from that of NACTs. 
Indeed, TI variants from peanut ACTs contained a significantly lower number of hydrophobic 
AAs and had a higher proportion of hydrophilic, basic, and acidic AAs compared to those 
encoded by peanut NACTs.   
 
To verify if these observations were also valid for other allergens, we repeated the same 
calculations for two other familiar sources of food allergens (soybeans and sesame seeds) and 
one major environmental allergen, the Dermatophagoides pteronyssinus house dust mite (Tables 
4, 5 and 6 and Supplementary material 2). In these three allergen sources, we found the same 
high-density patterns of RDD gaps spanning the entire ACT, as in peanut allergens. Similarly, 
their ACTs also had a significantly higher expression level and translated into significantly 
smaller proteins compared to NACTs. Finally, we observed the same differences in TI peptide 
AA composition between ACTs and NACTs with only one exception: in the sesame, the 
percentage of hydrophilic AA was not significantly different between ACTs and NACTs. Using 
in silico translation of TI gaps from both ACTs and NACTs, we verified that the 2-log increase 
in the TI peptide isoelectric point was, indeed, the consequence of gaps in all four allergen 
sources (data not shown). 
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Altogether, our observations indicate that, in all these four distinct allergen sources, transcripts 
encoding allergens translate into a higher, albeit variable, number of TI variants containing a 
cationic TI peptide at its carboxy-terminal end.  
 
It is the transcription infidelity variants of Ara h 2, but not the canonical allergen itself that 
induce the production of specific immunoglobulin E in mice. To experimentally verify the 
hypothesis that TI variants translated from gapped RNA contribute to protein allergenicity, we 
first focused on the peanut because of the well-established central role played by a single 
allergen ((Ara h 2; Uniprot accession Q6PSU2; LOC112707245 on the Arachis hypogea genome 
and 100% identical to our genome assembly) in about 90 % of peanut-allergic human patients 
(21). The transcripts encoding Ara h 2 contain 13 RDD gaps (Figure 3A). We produced 
recombinant Ara h 2 (rAra h 2) in its canonical sequence and three of its TI variants (v36, v38, 
and v40) translated from frameshifted cDNA constructions (Figure 3B). These four purified 
proteins were injected without adjuvant, at a 1-week interval, into groups of eight BALB/cByJ 
mice (400µg each) (Figure 3C); control rodents received only buffer vehicle injections. We then 
measured the levels of IgM, IgG and IgE directed against either the canonical (Figure 3D) or TI 
variants (Figure 3E) of Ara h 2 at various time points. All four proteins induced significant 
increases in Ara h 2 IgM and IgG levels relative to controls (Figure 3D). The increased 
subclasses of IgG were mainly IgG1 (Supplementary Material 3). It is only the injection of the 
three TI variants that increased the sIgE reactivity against both the canonical rAra h 2 (Figure 
3D) and its three variants (Figure 3E). In contrast, similar injections of the canonical rAra h 2 
caused no detectable increase in Ara h 2 sIgE reactivity (Figure 3D). Seventy-six days after the 
first injection, we challenged mice with their respective sensitizing proteins. We evaluated 
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symptomatic allergic reactions, as we previously described, by a total allergy score, the level of 
scratching during the first 30 min post-injection, and the decrease in body temperature (22). All 
three TI variants of Ara h 2 induced clinical allergic reactions after their respective sensitization, 
which were significantly more pronounced than those recorded in control- or canonical rAra h 2-
injected mice (Figure 3F). 
Although sensitizations with the canonical rAra h 2 did not induce a detectable increase in 
circulating sIgE, a challenge with this protein led to a clinical response that was significantly 
more noticeable than that of non-sensitized controls (Figure 3F). This observation was not 
surprising as canonical Ara h 2 injections induced the production of specific IgG, and adoptive 
transfer experiments have shown previously that clinical signs of allergy can also be IgG-
mediated in mice (23–25). 
We then used direct and inhibition western immunoblotting with canonical Ara h 2 as an 
inhibitor, to verify if the sIgE elicited by TI variants recognized the TI or the canonical segments 
of the Ara h 2 variants. We found that the canonical rAra h 2 nearly extinguished the sIgE 
reactivity towards the canonical rAra h 2, while it only reduced—but did not suppress—that 
present against TI variant linear epitopes (Figure 3G). With this set of experiments, we 
established that it is the TI variants of an allergen, and not its canonical version, that induce the 
sIgE production and clinical signs of allergy in sensitized mice; furthermore, we confirmed that 
the sIgE from Ara h 2-sensitized mice reacted with linear epitopes located on both canonical and 
TI segments of the TI variants.  
 
Adding a cationic transcription infidelity peptide to the carboxy-terminal end of a non-allergenic 
protein is sufficient to elicit the production of specific IgE in mice. We next tested if the 
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induction of sIgE could be experimentally-induced against a non-allergenic protein by adding a 
TI peptide to its carboxy-terminal end. We selected a peanut protein (ARR17L encoded by a 
gene in our Arachis hypogea genome assembly 100% identical to LOC107470167 in the Arachis 
duranensis genome encoding a two-component response regulator ARR17-like; see 
Supplementary Material 2); it is of a similar size as Ara h 2 (20 kDa), has no AA sequence 
identity with any known allergen, and it is encoded by a transcript without any identifiable RDD 
gaps. We thus produced two recombinant ARR17L proteins: one with the added carboxy-
terminal cationic TI peptide (ARR17L-TIP) and one with the non-cationic peptide resulting from 
the corresponding canonical translation (ARR17L-CAN) (Figure 4). Three injections, at a 1-
week interval, of 400 µg of either ARR17L chimera elicited the production of sIgM and sIgG 
against the respective chimera, but sIgE rose significantly only against the ARR17L-TIP (Figure 
4). Therefore, the mere addition of a cationic TI peptide to the carboxy-terminus of a non-
allergenic protein appears sufficient to induce the production of sIgE after injection into mice 
without any adjuvant. 
 
It is the concomitant, but not the sequential injections of transcription infidelity variants of Ara h 
2 that induce the production of specific IgE. A high diversity of TI variants appears to be a 
general characteristic of ACTs compared to NACTs (Tables 3 to 6). This finding implies that, in 
any given allergen preparation, several TI variants of the same canonical allergen will co-exist. 
We thus questioned if the different TI variants might “cooperate” to induce the production of 
sIgE. 
In Figure 5, we showed that injections of a cocktail of three TI variants and the canonical 
protein, each at a dose four-fold lower (100µg) than that used in the experiment reported in the 
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Figures 3 and 4 (400µg per injection) significantly increased the production of Ara h 2-specific 
IgM, IgG, and IgE. In contrast, the sequential injections, at the same 1-week interval, of each TI 
variant to achieve the same cumulative dose, only caused a significant increase in Ara h 2-
specific IgM and IgG without detectable specific IgE. These data suggest that the TI variants 
present in ACTs have a cooperative effect on the production of sIgE. Therefore, the injection of 
either a single TI variant at a high dose (400 µg) or the combination of three TI variants and the 
canonical Ara h 2 at low doses (100 µg each), are both sufficient to induce the production of IgE 
without the need for any adjuvant. 
 
The removal of low-abundance cationic proteins from bovine whey markedly reduces its ability 
to cause IgE production in mice. Bioinformatic data indicated that TI events in the peanut only 
affected a minute percentage (less than 0.5%) of transcribed mRNAs; assuming that all TI-
containing transcripts would be translated, we estimated that TI variants represent less than 4% 
of the total peanut protein content. As these TI variants are predicted to be cationic, their 
separation and removal based on a higher isoelectric point are therefore possible. 
To test such a method of TI variant depletion, we selected whey (i.e., lactoserum), a milk 
derivative devoid of caseins. Bovine whey was separated using ion-exchange chromatography 
into two fractions with an isoelectric cutoff set at 7.4. We first calculated that the fraction with an 
isoelectric point higher than this cutoff represented less than 5% of whey proteins, a finding 
consistent with our previous calculation of the proportion of TI variants among peanut proteins 
(see above). This cationic (C) fraction with a high isoelectric point had a profile in SDS-PAGE 
that was different from those of the total whey (W) and the low isoelectric point non-cationic 
(NC) fraction (Figure 6A).  
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In a first experiment, a low dose (60 µg) of either total, cationic and non-cationic whey fractions 
was administered to mice intra-gastrically to closely mimic the physiological conditions of milk 
exposure (Figure 6B). Remarkably, at that dose, only the cationic whey fraction—but not the 
total or non-cationic fractions— induced a statistically-significant increase in sIgE relative to that 
of control mice on Day 55 (Figure 6C).  
As there were notable inter-individual variations in the IgE response to this cationic whey 
fraction, we conducted a second experiment in which a higher number of mice was given either a 
high dose (3.5 mg) of total whey or a 25-fold lower dose (150 µg) of either cationic or non-
cationic whey fractions. We showed that the low dose of cationic whey induced the production 
of sIgE at the same level as that induced by the 25-fold higher amount of total whey (Figure 6D). 
In contrast, the ingestion of the low dose of non-cationic whey led to a significantly lower sIgE 
production with their titer plateauing between 35 and 42 days while that observed for total or 
cationic whey continued to increase over time significantly (Figure 6D). A limitation of our 
fractionation method, however, is that we cannot exclude that the non-cationic whey fraction 
might still contain some TI variants, as the addition of a cationic TI peptide might not always be 
sufficient to shift an entire variant’s isoelectric point above that of our 7.4 cutoff point. 
Altogether, our results suggest that proteins that trigger sIgE production in response to the 
ingestion of whey are present in this food's cationic fraction, which should include the TI 
variants of whey allergens. Nevertheless, we cannot eliminate the possibility that a difference in 
the identity of the proteins present in the cationic and anionic fractions also might have 




The analysis of RNA-DNA divergence gap patterns in the peanut transcriptome leads to the 
discovery of two previously-unreported yet prevalent allergens for peanut-allergic humans. To 
identify previously-unreported allergens, we screened the available peanut transcriptome for 
mRNAs encoding proteins not known currently as allergens, but that had an expression level, an 
RDD gap profile, and a TI segment AA composition suggesting that the translated canonical 
protein could be an allergen in peanut-allergic human patients. We discovered a transcript with 
12 RDD gaps and a gap density comparable to that of Ara h 2 (13 gaps spanning 312 nucleotides 
coding for a 19 kDa protein). The canonical sequence of this believed to be novel peanut allergen 
(NPA) encodes a predicted 23.4-kDa protein with a suspected S26 Type I signal peptidase 
domain (NCBI CD06530; Figure 7A). In the peanut wild ancestor Arachis duranensis, the 
LOC107473664 gene encodes this protein, which we designated as NPA23. This NPA23 has no 
sequence homology with any of the known peanut allergens, but it contains very short AA 
sequences shared with four allergens in the Allergome database (Figure 7A). Two of these 
allergens are uncommon, but there could be a potential cross-reactivity between the NPA23 with 
the cat allergen Fel d 2.0101 and the dog allergen Can f 3.0101. The canonical NPA23 protein 
was produced in E. coli and purified as a single product forming several oligomers, as shown by 
SDS-PAGE in Figure 7B. We found the sera of all ten children with clinical peanut allergy 
(among our patients; Table 7) to have detectable sIgE against this NPA23 on immunoblots, while 
only one in five atopic patients without a peanut allergy and none of five healthy controls had 
such detectable reactivity (Figure 7B). Of potential clinical relevance was that the observation 




Using the same approach, we found another peanut transcript with 47 RDD gaps, which encodes 
a putative 27.2 kDa canonical protein (NPA27) with no sequence identity with any of the known 
allergens. This NPA27 contains a thaumatin-like domain (NCBI CD09218, TLP-PA) that 
explains its low sequence homology with four other allergens (Supplementary Material 4). In the 
peanut wild ancestor Arachis ipaensis, the LOC107629116 gene encodes the NPA27. We 
produced recombinant NPA27 in E. coli, and this allergen was recognized by serum sIgE from 
peanut-allergic patients, albeit at an intensity and frequency lower than that of NPA23 
(Supplementary Material 4). 
 
To more precisely estimate the prevalence of the IgE seropositivity to the NPA23 and 27, we 
tested a larger group (including previous patients tested above by immunoblotting) of peanut-
allergic and tolerant children by ELISA (Table 7). Altogether, we detected sIgE against NPA23 
and 27, respectively, in the serum of 24/52 (46 %) and 25/52 (48 %) peanut-allergic children, 10 
and 8 (26 % and 21 %) of 38 peanut-tolerant atopic but in none of the six healthy children 
(Figure 7C); these proportions are significantly higher in peanut-allergic than in peanut-tolerant 
atopic and control children (p < 0.01 and < 0.03 for NPA23 and NPA 27, respectively). If we 
were to use a cutoff of a mean ± 2 standard deviations of the IgE concentration obtained in 
peanut-tolerant atopic children, the proportion of children with positive sIgE reactivity against 
NPA23 would be 18/52 (35%) peanut-allergic but only 2/38 (5 %) of peanut-tolerant atopic 
children. Similarly, that toward NPA27 would be above this threshold in 12/52 (23 %) peanut-
allergic but only 3/38 (8%) peanut-tolerant atopic children. Therefore, both immunoblotting and 
ELISA results concur in demonstrating that both NPA23 and 27 are two previously-unreported 





The specific IgE of peanut-allergic children recognize both canonical and transcription infidelity 
segments of Ara h 2. We hypothesized that if TI proteins were responsible for the development 
of peanut allergy in human patients, some of their sIgE should be directed against the cationic 
carboxy-terminal TI segment of the Ara h 2 TI protein variants.  
We first tested the sIgE reactivity against both the canonical Ara h 2 and three of its TI variants 
in a cohort of 51 children with clinically-proven peanut allergy, 37 peanut-tolerant atopic and six 
healthy controls (among our patients; Table 7). In peanut-tolerant atopic or healthy controls, we 
found sIgE above the cut-off (mean + 2SD of peanut-tolerant children) against rAra h 2, and its 
v36, v38 and v40 variants in 1/37 (3%), 2/43 (5%), 1/39 (3%) and 2/38 (3%) respectively (data 
not shown). In contrast, we found sIgE against rAra h 2, and its v36, v38 and v40 variants in 
30/37 (81%), 37/51 (73%), 33/46 (72%) and 34/42 (81%) of peanut-allergic children, 
respectively (Figure 8A).  
The difference between the sIgE levels against each of the four proteins was highly significant (p 
< 10-6) between peanut-tolerant and peanut-allergic children. In the seven peanut-allergic 
children without detectable rAra h 2 sIgE by ELISA, we found sIgE to the v40 variant in only 
one patient. Finally, the sIgE binding to the v40 variant was significantly higher than that 
measured against the canonical Ara h 2, despite this particular TI variant missing one of the eight 
Ara h 2 immuno-dominant epitopes (26). 
We then conducted ELISA inhibition experiments using the sera of ten peanut-allergic children. 
These inhibition assays showed that an excess of canonical Ara h 2 inhibited significantly more 
of the reactivity to the identical canonical protein than that against its three TI variants (Figure 
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8B). These observations were confirmed using a 2-fold higher or lower concentration of 
inhibiting canonical Ara h 2 (data not shown). Of note is that the proportions of IgE specific for 
the TI segment of each TI variant varied between patients (Table 8). These inhibition 
experiments indicated that, on average, 20 % of IgE bound the TI segment of Ara h 2. 
Altogether, these observations suggested that, as in mice, some of the sIgE of peanut-allergic 
humans recognize both the canonical and TI Ara h 2 variants. Furthermore, the sIgE reactivity 
against the TI segment of an Ara h 2 variant was always associated with one against the 
canonical segment.  
 
Children with IgE-negative milk allergy have detectable IgE against the cationic transcription 
infidelity protein-enriched fraction of lactoserum. Children with milk allergy are diagnosed after 
the development of clinical signs upon the ingestion of milk and their resolution with the 
avoidance of dairy products (Table 9). While most of the children with clinical milk allergy have 
detectable sIgE (“IgE-positive milk allergy”), some do not (the so-called “IgE-negative milk 
allergy” or “non-IgE-mediated milk allergy”). We hypothesized that the lack of detection of sIgE 
in children with “IgE-negative milk allergy” could be due to an insufficient amount of TI 
proteins in the standard milk extract used for sIgE detection by ELISA. As shown in the 
preceding sections, TI variants of allergens are cationic, so we processed bovine whey 
(lactoserum) based on an isoelectric point of 7.4 to separate its anionic from its cationic fraction. 
We tested by ELISA the sera of seven children with "IgE-negative milk allergy," seven with 
"IgE-positive milk allergy," and ten controls for IgE directed against these two lactoserum 
fractions. As shown in Figure 9, the ratio of cationic-to-anionic IgE reactivity was significantly 
higher in “IgE-negative” than in “IgE-positive” milk-allergic children (P < 0.005) and other 
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allergic children (P < 0.05). This observation suggests that in the "IgE-negative milk allergic 
children," the previously-undetectable IgE are directed more often against the cationic fraction of 
lactoserum enriched in low-abundance TI allergens than to its anionic fraction that contains 




In this paper, we provide eight independent lines of evidence supporting the concept that IgE 
production is not due to abundant allergenic proteins translated from their canonical RNA, but 
that it is induced by the presence of low-abundance TI variants translated from gapped 
transcripts. Herein, we showed that: 1) the RDD gap rates are significantly higher in an 
allergenic legume (the peanut) compared to two other legumes of lower allergenicity; 2) at the 
single transcript level, the RDD gap density is significantly higher in allergen-coding than in 
non-allergen coding mRNAs and this observation was verified in the peanut, the soybean, the 
sesame, as well as in a classic environmental allergen, the Dermatophagoides pteronyssinus 
house dust mite; 3) three recombinant non-glycosylated TI variants of the major peanut allergen 
Ara h 2, but not the protein resulting from canonical transcripts, induce IgE isotype switching in 
mice at low doses when added concomitantly, but also when added singly at a higher dose; in 
both cases, adjuvants were not needed; 4) adding a TI peptide to a non-allergenic peanut protein 
is sufficient to cause IgE production—again without the need for an adjuvant; 5) the removal of 
the cationic peptide-enriched fraction from whey, which is expected to contain its putative TI 
variants, markedly reduces its capacity to induce sIgE production in mice; the whey fraction 
enriched in cationic peptides is sufficient to induce sIgE at a dose 25-fold lower than that of total 
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whey; 6) the analysis of the RDD gap pattern of peanut transcripts led to the identification of two 
previously-unknown prevalent peanut allergens; 7) the sIgE of children with a clinically-proven 
peanut allergy are reactive, not only with the canonical Ara h 2, but also with the TI segments 
present on at least three Ara h 2 TI variants; 8) Finally, we established that all seven tested 
children with “IgE-negative milk allergy” have, in fact, detectable sIgE against the cationic 
fraction of whey, which is enriched in TI proteins that are typically in low-abundance in standard 
milk extracts used for ELISA. 
 
Herein, we report for the first time that a single base gap is a frequent TI event that causes the 
translation of cationic peptides because of the asymmetric degeneracy of the universal genetic 
codes favoring the translation of basic AAs. Furthermore, we showed that a high gap density and 
an overall increase in the RDD gap rate are both associated with allergenicity and that these 
characteristics are not restricted to the peanut, as they are also present in all four tested allergen 
sources, irrespective of their ontogeny. Altogether, these observations indicate that the AA 
motifs that initiate allergen-specific IgE production are likely absent in proteins translated from 
their canonical RNA; this is a possible explanation for the long-lasting, yet fruitless, quest for 
AA patterns that would distinguish allergens from non-allergenic proteins. While abundant 
canonical allergens might not initiate sIgE production sensu stricto, they can provoke clinical 
manifestations of the disease, however. Indeed, we have shown previously that the canonical Ara 
h 2 can induce positive skin prick tests in peanut-allergic patients (27).  
 
Previous reports have shown that transcriptional substitutions occurring only at the RNA level 
occur commonly in human subjects and translate into variants of canonical proteins (8, 11). For 
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example, we established earlier that RDD substitutions occur more commonly in cancerous than 
in normal healthy cells (15). Furthermore, frameshifted RNA resulting in GA deletions are also 
present in neurological disorders (28–30). Indeed, the RNA polymerase II is error-prone (for a 
review, see (31, 32)), and its rate of error increases with the level of gene expression (13). 
Interestingly, we established herein that transcripts encoding allergens are more abundant than 
those coding for non-allergenic proteins, and this could increase the rate of transcription errors. 
Furthermore, our data revealed that RNA frameshifts resulting from single base gaps are a rather 
common phenomenon that does not occur randomly, but preferentially at sites of A and T 
repeats, and only when the composition of surrounding bases is permissive for slippage of the 
RNA polymerase II. This motif of six influential bases is similar to that previously described for 
TI substitutions, and it corresponds to the portion of DNA melted by the RNA polymerase II 
during the transcription process (15). With the advent of the CRISPR-Cas9 that allows for 
genomic editing (33), a modification of these DNA motifs that are conducive to base deletion—
perhaps by changing a base without altering the AA sequence itself—would, at least 
theoretically, reduce the transcriptional slippage. Such reduction would then decrease the sIgE 
production and could help design foods of lower allergenicity. In the same perspective, the 
construction of artificial genes not permissive to TI and coding for therapeutic recombinant 
proteins could reduce their allergenic potential.   
 
The data reported herein could help further the understanding of the mechanisms underlying the 
development of sensitization to allergens. Indeed, we provided evidence that, in both rodents and 
humans, cationic TI peptides relatively depleted in hydrophobic AAs play a critical role in the 
induction of sIgE production. These molecular patterns do not require an adjuvant, thereby 
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suggesting that they, by themselves, carry one of the hypothetical “danger signal(s)” for an IgE 
production switch. Herein, we provide simple biochemical probes that might enable future 
dissections into the mechanism involved in regulating the complex biology of IgE. Nevertheless, 
our findings do not rule out that other mechanisms (i.e., protease activity, auto-adjuvant 
properties, and others) might also contribute to IgE production (34, 35). 
Furthermore, not all cationic peptides inducing the production of sIgE are the result of the 
translation of frameshifted RNA. For example, there is a cluster of positively-charged residues 
resulting from the canonical translation of one of the isoforms of the major allergen ovalbumin 
(36). Finally, whether or not a specific TI pattern similar to that found in allergens is also present 
on helminth transcripts whose translated proteins also induce specific IgE production needs to be 
investigated (37). 
 
In this paper, we introduced several applications that could be clinically-relevant for human 
allergic patients. Firstly, with the availability of next-generation sequencing and recently 
developed procedures to better distinguish bona fide RDDs from mere sequencing errors (14), a 
simple method is now available to estimate the potential allergenicity of different sources and the 
allergenic potential of individual proteins. This approach might prove useful to evaluate the 
allergenic risk of new foods or ingredients.  Secondly, the combination of a high-density gap 
together with a low hydrophobicity of TI peptides provided a simple method to rapidly identify 
previously-undescribed candidate allergens and explain unusual situations of allergy. For 
example, our previously-unreported NPA23 has an AA sequence homology with four non-peanut 
allergens, including a Fel d 2 isoform. With such information, we found it no longer surprising 
that one of our peanut-tolerant atopic child (#19) with a detectable sIgE against NPA23 was, in 
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fact, clinically-allergic to cats. This observation raised the hypothesis of a possible clinically-
relevant cross-reactivity between the NPA23 and Fel d 2 in some patients, a topic deserving of 
further investigations. Thirdly, we presented data that suggested that one could potentially reduce 
the allergenicity of known allergens. Indeed, using the example of whey, we showed that the 
removal of cationic proteins based on their elevated isoelectric point reduces the stimulus for 
sIgE production against the entire food allergen. Such a strategy, if expandable industrially, 
could markedly reduce food allergenicity while preserving over 95% of the entire dietary (and 
standard) protein content. This strategy would be distinct from the current hydrolysis processes 
that prevent clinical manifestations of the disease by reducing the size of allergens to a point 
where the aggregation of IgE anchored to the FcεRI would no longer be possible (38). Before the 
industrial expansion of a cationic protein-depleted hypoallergenic milk, a deeper understanding 
of milk TI variants, including those of the casein allergens, is needed. Finally, our positive 
detection of IgE directed against the cationic fraction of whey—a casein-free milk product—
permits a logical explanation of why some children with "IgE-negative" milk allergy do not have 
detectable sIgE when tested with standard milk extracts containing low amounts of low-
abundance TI proteins. If one were to expand these observations to other clinical allergies in 
which patients do not have detectable IgE against the relevant allergens, one could envision the 
development of TI-enriched allergen extracts that would have a higher sensitivity to detect the 
early or uncommon “IgE-negative” allergies in human or animal patients. 
 
In conclusion, the results of the above experiments introduced what we believe is a novel 
mechanism that contributes to the allergenicity of proteins. Further research is underway to 
determine the precise AA composition(s) and sequence(s) and respective molecular recognition 
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patterns that control IgE isotype switching. Secondly, one also needs to explain why individuals 
react differently upon exposure to allergenic TI variants. In fine, we speculate that not only 
genetic (39, 40), but also microbiota (41) and environmental (42) factors contribute with TI in 




Human patient characteristics 
The children whose sera were included in the current study had been referred to the outpatient 
clinic of the Internal Medicine, Clinical Immunology and Allergology Unit of the Nancy 
University Hospital, France, to the Allergology Center from the Saint Vincent de Paul Hospital 
in Lille, France and the Pneumology and Allergology Department of the Angers University 
Hospital in France. The clinical and biological characteristics of patients and controls are 
summarized in Table 7 for peanut (21) and Table 9 for milk. All peanut-allergic children were 
diagnosed based on both a positive peanut double-blinded placebo-controlled food challenge 
(DBPCFC) performed as previously described (21) and a detectable sIgE reactivity toward major 
peanut allergens (Thermo-Fisher Scientific, Uppsala, Sweden). The control groups included 38 
atopic and six healthy children. The 38 atopic patients had either a negative peanut DBPCFC 
with 10 g of peanut or the documented regular absorption of peanuts without the trigger of 
clinical symptoms; the peanut-sIgE reactivity of these atopic children is also shown in Table 7. 
Cow’s milk-allergic children were diagnosed because of the development of clinical symptoms 
after the ingestion of milk and their improvement or resolution after cow’s milk avoidance; they 
were subdivided based on a detectable (i.e., IgE-mediated milk allergy) or undetectable (i.e., 
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non-IgE-mediated milk allergy) serum sIgE reactivity toward cow’s milk extract (Thermo-Fisher 
Scientific, Uppsala, Sweden). Among the seven controls with other allergies, two were allergic 
to peanuts, two to house dust mites, and three to birch or grass pollen.   
 
 
Bioinformatic analyses  
To identify TI events, we performed bioinformatic annotations of transcriptomes of several 
allergens using Illumina sequencing data, as previously described but with modifications 
appropriate to curate short reads (see Supplementary Material 2) (15). The sequencing coverage 
of RNA-derived sequences was used as a proxy for transcript abundance. To detect RDDs, we 
examined each mRNA position for its concordance with the DNA reference sequence. Not only 
were the 12 possible base substitutions found in all four allergen sources, but insertions and gaps 
in the mRNA that were not present in the respective reference DNA were also detected. We 
herein only report the RDD gaps that occurred within the open reading frame (i.e., those that 
might be translated into a protein). To estimate the overall TI burden in any given source, we 
used the RDD rate, which we calculated as the sum of events at each position divided by the sum 
of reads at any given position.  
 
Protein preparations 
Production of recombinant proteins 
Recombinant proteins, except for Ara h 2, were produced as N-terminal-hexa-histidine-tagged 
proteins in BL21 Escherichia coli according to standard procedures with the modification that 
clones were engineered toward E. coli codon usage to increase their expression levels. The 
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canonical Ara h 2 was produced with the same method except that the histidine-tag was 
positioned at the C-terminus. The proteins were then purified from inclusion bodies by 
immobilized metal ion affinity chromatography (His Trap FF column, GE Healthcare, Vélizy, 
France). Recombinant Ara h 2 and its variants were refolded on the column by a decreasing 
linear gradient from 8 to 0 M urea and eluted in native phosphate-buffered saline (PBS: 30 mM 
sodium phosphate, 150 mM NaCl, pH 7.4) containing 500 mM imidazole and 20% glycerol. 
Imidazole was subsequently removed using a Zeba Desalt Spin column (Thermo Fisher 
Scientific, Rockford, IL, USA) to enable the storage of rAra h 2 and its variants in a native PBS 
containing 10% glycerol. The recombinant proteins ARR17L-CAN, ARR17L-TIP, NPA23, and 
NPA27 (see below for their characterization) were eluted from the columns in a denaturing PBS 
containing 500 mM imidazole, 6 M urea and 2 mM beta-mercapto-ethanol. Imidazole was 
removed using a Zeba Desalt Spin column to enable the storage of ARR17L-CAN and ARR17L-
TIP in a denaturing PBS containing 2 M urea and that of NPA23 and NPA27 in a denaturing 
PBS containing 6 M urea and 2 mM beta-mercapto-ethanol. Protein concentrations were 
determined using a protein assay kit (Bio-Rad, Hercules, CA, USA), and the final molecular 
weight of the recombinant purified proteins was verified by 12% SDS-PAGE (NuPAGE; 
Invitrogen, Saint Aubin, France) after Coomassie blue staining. Endotoxin concentrations were 
measured for all recombinant proteins—except for NPA23 and NPA27 that were used solely for 
in vitro testing—using the gel-clot Limulus Amebocyte Lysate (LAL) method and ENDOSAFE 
LAL reagents (Charles River Endotoxin Microbial Detection Europe, Ecully, France). Endotoxin 





The whey powder (Euroserum) was dissolved in phosphate buffer (10 mM sodium phosphate pH 
7.4), then the pH was checked, and the protein concentration was determined using a protein 
assay kit (Bio-Rad, Hercules, CA, USA). A blank gradient was performed on the cation-
exchange-column (HiTrap SP FF, GE Healthcare, Vélizy, France) connected to a 
chromatography apparatus (Akta Xpress, GE Healthcare, Vélizy, France) using (10 mM sodium 
phosphate pH 7.4) as a binding buffer and (10 mM sodium phosphate, 1 M NaCl, pH 7.4) as 
elution buffer. A protein amount corresponding to 50% of the binding capacity of the column 
was injected, and the flow-through (containing proteins with isoelectric point ≤ 7.4) was 
collected. After a washing step with the binding buffer, the column was eluted with the elution 
buffer, and the fractions (containing proteins with isoelectric point > 7.4) were collected. The 
flow-through and elution pools were buffer-exchanged against phosphate-buffered saline (PBS: 
30 mM sodium phosphate, 150 mM NaCl, pH 7.4), and the protein concentration was determined 
as above. The flow-through (non-cationic fraction) and elution (cationic fraction) pools were 
aliquoted before storage at -20°C. 
 
Mouse studies 
Mouse anaphylaxis model 
Female BALB/cByJ mice were purchased from the Charles River Breeding Centre (L'Arbresle, 
France). Blood samples were collected, and serum was obtained and stored at –20°C until 
analysis. 
Four-week-old mice were sensitized by intraperitoneal injection of 400 µg of recombinant rAra h 
2 and its TI variants (8 per group) in PBS with 10% glycerol (VWR, Fontenay-sous-Bois, 
France) once a week for 4 weeks (Figure 3). After sensitization, mice were challenged by 
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intraperitoneal injections of 350 µg of their sensitizing protein. Naive mice injected with the 
buffer were used as negative controls. Rectal temperature changes and scratching were measured 
to evaluate clinical allergic reactions, as described previously (22). In another experiment, ten 
14-week-old mice received injections of a mixture of rAra h 2 and its TI variants v36, v38, and 
v40 (100 µg of each) in PBS containing 10% glycerol once a week for 4 weeks. Meanwhile, and 
as a comparator, ten other mice were injected sequentially with 400 µg each of Ara h 2-v36 
(week 1), Ara h 2-v38 (week 2), Ara h 2-v40 (week 3) and the canonical rAra h 2 on week 4 
(Figure 5).  
We also injected five 7-week-old mice with the TI peptide-conjugated non-allergenic protein 
ARR17L-TIP and five others with this protein conjugated with the corresponding canonical 
peptide (ARR17L-CAN), both at 400 µg in PBS containing 2M urea, once a week for 3 weeks 
(Figure 4). Finally, we administered intragastrically native or its cationic or non-cationic whey 
fractions, along with 4µg of cholera toxin (Servibio, Les Ulis Courtaboeuf) to 4-week-old mice 
once a week for six weeks (see the number on Figure 6 C, D). 
 
Mouse ELISAs 
We assayed the specific immunoglobulins (Ig) to canonical and TI variants of rAra h 2 and 
ARR17L by ELISA. Plates (Maxisorp, Dutscher, Brumath, France) were coated for 1 h at 37°C 
with 1 µg protein per well. After each step, plates were washed three times with PBS containing 
0.1% Tween 20 (PBST) (Sigma-Aldrich, Saint Quentin Fallavier, France). Plates were then 
blocked for 1 h and incubated with diluted samples in PBS containing 2% milk and 0.05% 
Tween 20 (PBSTM) for 2 h (200 rpm, 37°C). Allergen-specific IgM and IgG were detected by 
alkaline phosphatase–labeled goat anti-mouse IgM and fragment crystallizable (Fc) IgG (Catalog 
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n°a9688 and a1418, Sigma-Aldrich, Saint Quentin Fallavier, France), respectively. Specific 
isotypes of IgG were detected by alkaline phosphatase–labeled goat anti-mouse IgG1, IgG2a, 
IgG2b, IgG2c, and IgG3 (catalog n° 1070-04, 1080-04, 1090-04, 1079-04 and 1100-04 
Clinisciences, Nanterre, France), respectively. Bound IgE was detected by HRP-labeled goat 
anti-mouse IgE (catalog n°1110-05 Clinisciences, Nanterre, France). The development was 
performed with TMB (3,3’,5,5’-tetramethylbenzidine, Fisher Scientific, Illkirch, France) for 
HRP and pNPP (p-nitrophenyl phosphate, Sigma-Aldrich) for alkaline phosphatase. 
 
Western blot inhibition 
One microgram of Ara h 2, Ara h 2-v36, and Ara h 2-v40 and three micrograms of Ara h 2-v38 
were separated by 12% SDS-PAGE (NuPAGE) under denaturing and reducing conditions and 
transferred to polyvinylidene difluoride membrane (0.45 µm, GE Healthcare, Buckinghamshire, 
UK). After blocking with Tris-buffered saline Tween (TBST: 100 mM Tris [pH 7.5], 154 mM 
NaCl, 0.1% [v/v] Tween 20] containing 5% [w/v] defatted milk [TBSTM]), membranes were 
incubated with a pool of sera from mice immunized with Ara h 2, Ara h 2-v36, Ara h 2-v38 or 
Ara h 2-v40 diluted 1:90 in TBSM and pre-incubated overnight with 200 µg/mL of Ara h 2. 
Membranes were washed with TBST and incubated with horseradish peroxidase (HRP)-labeled 
polyclonal anti-mouse IgE (catalog n° 1110-05 diluted 1:3000 in TBSTM, Southern Biotech, 
Birmingham, AL, USA). After washing, IgE-reactive bands were revealed by 
chemiluminescence (ECL Advance, GE Healthcare). 
 
Human studies 
ELISA and ELISA inhibition 
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We determined the sIgE against NPA23, NPA27, Ara h 2, and its variants v36, v38, and v40, and 
against the anionic and cationic whey fractions by ELISA. Plates (Maxisorp) were coated 
overnight at 4°C with 2.5, 5.0, 1.0, 2.5, 4.0, 1.0, 0.5 and 0.5 µg protein per well, respectively. 
After each step, plates were washed three times with PBST. Plates were then blocked for 2 h at 
37°C and incubated with diluted human serum samples in PBSTM or PBST-fish gelatin 1% for 
whey fractions for 2 h at 37°C. Bound sIgE was detected by HRP-labeled polyclonal anti-human 
IgE (catalog n° 074-1004 diluted 1:5000, KPL SeraCare, Gaithersburg, MD, USA) and 
developed with TMB. The results of this ELISA had been shown beforehand to match those of 
the commercially-available ImmunoCap, even though the former required a 20-fold lower serum 
amount than the latter. The peanut sIgE ELISA inhibition assays were performed as described 
above except that the diluted sera were pre-incubated overnight with large excesses (50, 100, or 
200 µg/mL) of the canonical rAra h 2. 
 
Immunoblotting  
Four micrograms of the peanut allergens NPA23 and NPA27 were separated by 12% SDS-
PAGE (NuPAGE) under denaturing and reducing conditions and stained with Coomassie blue or 
transferred to a polyvinylidene difluoride membrane (0.45 µm, GE Healthcare, 
Buckinghamshire, UK) for immunoblotting. After blocking with Tris-buffered saline Tween 
(TBST: 100 mM Tris [pH 7.5], 154 mM NaCl, 0.1% [v/v] Tween 20] containing 5% [w/v] 
defatted milk [TBSTM]), membranes were incubated with the children’s sera diluted 1:50 in 
TBSTM. Membranes were then washed with TBST and incubated with horseradish peroxidase 
(HRP)-labeled polyclonal anti-human IgE (catalog n° 074-1004 diluted 1:6000 in TBSTM, KPL 
SeraCare, Gaithersburg, MD, USA), as described previously (28). After washing, IgE-reactive 
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bands were revealed by chemiluminescence (ECL Advance, GE Healthcare). Negative control 





The Chi-squared and Fisher exact tests were used to determine the statistical significance of 
differences in proportions. A Shapiro-Wilk normality test was used to assess the distribution of 
data. When a normal distribution was present and there was not any difference between 
variances with a F-test of equality of variance, two-sample t-tests were used to compare 
differences between the means of the two populations. In case of different variances between 
populations, we used a Welch two-sample t-test. When non-normal distributions were observed, 
a Mann-Whitney U test was used with unpaired samples and a Wilcoxon signed-rank test with 
paired samples. In case of need for multiple testing, p-values were adjusted with a Holm-
Bonferroni procedure to control the family-wise error rate. P-values are indicated by *p < 0.05, 
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Figures and figure legends 
Figure 1. RNA-DNA divergence (RDD) gap rates in legumes. (A) Method of calculation of 
the RDD gap rates. (B) RDD gap rates related to the numbers (indicated as n) of A and T repeats 
for peanut, soybean and green bean. (C) Peanut RDD gap rates related to the numbers of A and T 
repeats. (D) Base composition surrounding (–10 and +10) RDD gap positions (b0). T-test, Welch 
T-test and Mann-Whitney tests with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, ***p < 





Figure 2. Theoretical and observed AA sequence compositions in peanut TI variants. (A) 
The in silico translation of peanut RNA with identified gaps showed that peptides translated from 
frameshifted RNA contained 4.4% acidic AAs and 16% basic AAs. Mole percentages were 
calculated using Pepstats from EMBOSS. (B) Impact of AA composition on the isoelectric point 
of TI peptides. Welch T-test with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, ***p < 








Figure 3. Evaluation of the immunogenicity of canonical and transcription infidelity 
variants of Ara h 2. (A) Distribution of 13 TI gap events over the Ara h 2 mRNA (red lines); 
the major Ara h 2 epitopes are shown in blue boxes, and they are numbered according to the 
recommended nomenclature (43). The AA sequences of Ara h 2 epitopes are shown in open 
boxes. (B) Proteins injected. The same color for each respective protein is used in panels B, D, E 
and F (C) Immunization protocol. (D) Canonical Ara h 2-specific antibodies. (E) Ara h 2 TI 
variant-specific antibodies. Color legend in (C) and (D): control mice (black), mice sensitized 
with Ara h 2 (red), Ara h 2-v36 (green), Ara h 2-v38 (yellow), and Ara h 2-v40 (blue). (D) and 
(E) figures represent means + SEM while in (E) lines correspond to the means minus those of 
Ara h 2 sensitized mice. (F) Total allergy, body temperature, and scratching scores after 
challenge in sensitized mice. Data presented as means + SEM (G) IgE western immunoblotting 
of rAra h 2 and the three TI variants with sera of mice immunized with Ara h 2-v36 (left), v38 
(middle) and v40 (right). The inhibition by the canonical rAra h 2 is indicated by "+." 
Single experiment with eight mice per sensitization group; T-test, Welch T-test and Mann-
Whitney tests with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, ***p < 0.001. (F) Box-






Figure 4. Effect of the addition of a transcription infidelity peptide to a nonallergenic 
protein. Levels of specific immunoglobulins directed against ARR17L-TIP (transcription 
infidelity peptide) and ARR17L-CAN (corresponding canonical sequence) in mice sensitized by 
intraperitoneal injection on days 0, 7, and 14. Single experiment with five mice per sensitization 
group; Paired T-test and Wilcoxon signed rank test with Holm-Bonferroni correction: *p < 0.05, 
**p < 0.01, ***p < 0.001. Box-and-whisker plot: box = interquartile range, bar = median, 
whiskers = 95% CI. 
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Figure 5. Comparison of the effect of combined or sequential injections of transcription 
infidelity peptides. Ara h 2 antibody levels in control mice and those injected with a combined 
dose of 400 µg (100 µg of each of four TI proteins) or the sequential injection of 400 µg of each 
protein at a 1-week interval. Single experiment with ten mice per sensitization group; T-test, 
welch T-test and Mann-Whitney tests with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, 









Figure 6. Differential allergenicity of whey fractions separated by their charges. (A) 
Coomassie-stained of an SDS-PAGE with 10 µg of either total, non-cationic (isoelectric point < 
7.4), and cationic (isoelectric point > 7.4) whey fractions. (B) Gastric administration and blood 
sampling schedule of whey (W), cationic (C), and non-cationic fractions (NC). (C) Serum sIgE 
response in BALB/cByJ mice that had ingested the same 60 µg of either total, cationic, and non-
cationic whey fractions. (D) IgE response of mice given either 3.5 mg of total whey or 150 µg of 
cationic and non-cationic whey fractions. Single experiment with 36 mice (C) and 106 mice (D). 






Figure 7. Discovery of two previously-unreported peanut allergens (NPA) using their 
transcription infidelity profiles. (A) Genomic and protein sequence characteristics of NPA23. 
The table lists the known allergens with sequence similarity to NPA23 in the Allergome 
database. (B) First lanes on the left: Coomassie blue staining showing purified NPA23 proteins 
(4 µg). The upper bands are believed to be NPA23 multimers. Center and rightmost lanes, IgE 
western immunoblotting with sera of peanut-allergic and -tolerant children (atopic and non-
atopic controls). (C) Specific IgE directed towards recombinant NPA23 using sera of peanut-






Figure 8. Specific IgE against canonical and transcription infidelity variants of Ara h 2. (A) 
Serum sIgE reactivity of 52 peanut-allergic children towards Ara h 2 and its three TI variants 
measured by ELISA. (B) Percentage of inhibition by canonical Ara h 2 of the IgE reactivity to 
the canonical and v36, v38, and v40 Ara h 2 variants in ten peanut-allergic patients. Paired T-
Test and wilcoxon signed rank test with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, 





Figure 9. IgE reactivity of milk-allergic children to charge-separated whey fractions. Sera 
from children (n = 7) with a clinical allergy to milk but undetectable milk-specific IgE using 
standard milk extracts ("IgE- milk allergy”) were found to have, in fact, IgE that reacted more to 
the TI protein-enriched cationic fraction of whey than to its anionic fraction containing the 
canonical proteins. The reverse was seen in children with milk allergy and detectable milk-
specific IgE (n = 7) and children with other allergies (n = 7); ratios from non-atopic children (n = 
3) were inconclusive. T-test with Holm-Bonferroni correction: *p < 0.05, **p < 0.01, ***p < 







Table 1: Changes in AA composition in proteins translated from frameshift are explained 
by probabilities of gain, loss, and conservation of residues. Acidic AAs are D and E and Basic 









Acidic 0.036 0.120 0 







Table 2: Predicted and observed AA composition in peanut canonical and TI peptides. 
Acidic AAs are D and E and Basic AA are R, K and H. 
 
 
Peanut Canonical TI peptides 
 Observed Observed Theoretical 
Acidic AA % 11.5 4.4 0 






Table 3: Comparison of allergen and non-allergen transcripts for peanut. The number of 
AAs indicates the protein size; the transcript expression is expressed in percentages of reads per 
kilobase per million mapped reads (RPKM), the highest expression serving as a reference; the 
gap diversity corresponds to the number of gaps taking into account the protein size. The range 
of occurrence of TI events has a value between 0 and 1, 0 indicating that it occurs at the N-
terminus and 1 at the C-terminus. The statistical test used for comparisons was a Welsh t-test 
with a Holm-Bonferroni correction. 
 
 Allergen genes (n=11) Non-allergen genes (n=10,224) 
p-value (allergens vs non 






Protein size 231 173 424 293 0.029 
Transcript expression levels 37.06 35.87 0.36 1.15 0.021 
Gap density 0.13 0.10 0.03 0.04 0.022 
Earliest occurrence of TI event              
(0 NH2 -> 1 COOH) 
0.07 0.06 0.21 0.22 0.0002 
Latest occurrence of TI event                
(0 NH2 -> 1 COOH) 
0.93 0.06 0.81 0.22 0.0002 
% of acidic AAs 6.01 5.36 4.57 5.51 2.117e-29 
% of basic AAs 15.62 9.07 13.72 10.35 8.942e-05 
% of hydrophobic AAs 40.47 12.17 49.99 14.68 0.003 





Table 4: Comparison of allergen and non-allergen transcripts for soybean. The number of 
AAs indicates the protein size; the transcript expression is expressed in percentages of reads per 
kilobase per million mapped reads (RPKM), the highest expression serving as a reference; the 
gap diversity corresponds to the number of gaps taking into account the protein size. The range 
of occurrence of TI events has a value between 0 and 1, 0 indicating that it occurs at the N-
terminus and 1 at the C-terminus. The statistical test used for comparisons was a Welsh t-test 
with a Holm-Bonferroni correction. 
 
 Allergen genes (n=18) Non-allergen genes (n=24,238) 
p-value (allergens vs non-






Protein size 334 178 500 361 0.003 
Transcript expression levels 2.31 2.31 0.06 0.29 0.003 
Gap density 0.06 0.02 0.02 0.03 5.18e-07 
Earliest occurrence of TI event              
(0 NH2 -> 1 COOH) 
0.07 0.08 0.26 0.26 2.024e-07 
Latest occurrence of TI event                
(0 NH2 -> 1 COOH) 
0.87 0.28 0.74 0.25 0.027 
% of acidic AAs 5.72 6.23 4.58 5.57 0.003 
% of basic AAs 16.20 10.69 13.98 10.98 0.001 
% of hydrophobic AAs 43.07 15.5 49.04 15.31 1.287e-11 






Table 5: Comparison of allergen and non-allergen transcripts for sesame. The number of 
AAs indicates the protein size; the transcript expression is expressed in percentages of reads per 
kilobase per million mapped reads (RPKM), the highest expression serving as a reference; the 
gap diversity corresponds to the number of gaps taking into account the protein size. The range 
of occurrence of TI events has a value between 0 and 1, 0 indicating that it occurs at the N-
terminus and 1 at the C-terminus. The statistical test used for comparisons was a Welsh t-test 
with a Holm-Bonferroni correction. 
 
 Allergen genes (n=9) Non-allergen  genes (n=17,285) 
p-value (allergens vs non- 






Protein size 316 179 494 344 0.09 
Transcript expression levels 70.86 29.57 0.68 1.39 0.001 
Gap density 0.04 0.01 0.03 0.04 0.09 
Earliest occurrence of TI event              
(0 NH2 -> 1 COOH) 
0.18 0.16 0.19 0.22 1 
Latest occurrence of TI event                
(0 NH2 -> 1 COOH) 
0.95 0.02 0.80 0.22 4.248e-07 
% of acidic AAs 5.72 5.17 4.64 5.61 0.09 
% of basic AAs 17.14 10.97 14.84 11.20 0.09 
% of hydrophobic AAs 44.98 12.47 48.51 14.49 0.009 
% of hydrophilic AAs 31.80 12.04 32.00 14.31 1 





Table 6: Comparison of allergen and non-allergen transcripts for Dermatophagoides 
pteronyssinus house dust mite. The number of AAs indicates the protein size; the transcript 
expression is expressed in percentages of reads per kilobase per million mapped reads (RPKM), 
the highest expression serving as a reference; the gap diversity corresponds to the number of 
gaps taking into account the protein size. The range of occurrence of TI events has a value 
between 0 and 1, 0 indicating that it occurs at the N-terminus and 1 at the C-terminus. The 
statistical test used for comparisons was a Welsh t-test with a Holm-Bonferroni correction. 
 
 Allergen genes (n=17) Non-allergen genes (n=5,587) 
p-value (allergens vs non- 






Protein size 420 406 650 606 0.05 
Transcript expression levels 16.49 13.22 1.97 4.57 0.002 
Gap density 0.05 0.03 0.02 0.02 0.003 
Earliest occurrence of TI event              
(0 NH2 -> 1 COOH) 
0.16 0.22 0.34 0.25 0.007 
Latest occurrence of TI event                
(0 NH2 -> 1 COOH) 
0.87 0.10 0.71 0.24 8.955e-05 
% of acidic AAs 3.54 5.31 4.51 5.52 0.003 
% of basic AAs 13.95 9.20 12.43 9.01 0.007 
% of hydrophobic AAs 51.78 13.44 54.3 14.25 0.003 












Table 7. Characteristics of the human patient sera.  
Clinical and biological characteristics of all peanut-allergic patients and their controls. The 
diagnosis of peanut allergy was established based on a positive oral provocation and detectable 








 Mean SD Min Max Mean SD Min Max Mean SD Min Max   
Females 18    12    2      
Males 34    26    4      
Age 8.5 3.4 3.0 16.0 7.2 3.3 2.0 18.0 10.7 5.1 4.0 18.0   
Specific 
IgE (kU/L) 
            
  
Ara h 1 31.6 51.1 < 0.1 296 < 0.1 < 0.1 < 0.1 0.12 < 0.1 < 0.1 < 0.1 < 0.1   
Ara h 2 46.5 47.3 < 0.1 204 < 0.1 < 0.1 < 0.1 0.10 < 0.1 < 0.1 < 0.1 < 0.1   
Ara h 3 13.0 21.6 < 0.1 100 < 0.1 < 0.1 < 0.1 0.14 < 0.1 < 0.1 < 0.1 < 0.1   
Ara h 6 11.5 16.2 < 0.1 65.1 < 0.1 < 0.1 < 0.1 0.10 ND ND ND ND   
Ara h 7 4.0 9.5 < 0.1 48.1 < 0.1 < 0.1 < 0.1 0.12 ND ND ND ND   
Ara h 8 2.3 7.0 < 0.1 43.4 11.5 20.6 < 0.1 71.4 < 0.1 < 0.1 < 0.1 < 0.1   






Table 8. Percentage of IgE directed toward the TI segment of each TI variant in ten 
peanut-allergic children measured by ELISA. 
 
% of IgE reactivity with 
TI segment of variants 
Ara h 2-v36 Ara h 2-v38 Ara h 2-v40 
Patient 1 21.7 13.1 13.3 
Patient 2 16.5 8.5 11.3 
Patient 3 29.2 24.6 23.0 
Patient 4 20.6 12.5 21.2 
Patient 5 27.2 7.9 7.1 
Patient 6 22.2 17.4 25.1 
Patient 7 20.2 19.2 15.4 
Patient 8 34.0 25.3 20.5 
Patient 9 23.6 23.7 29.8 











Table 9. Characteristics of milk-allergic patients and their controls. Here again, the 
diagnosis was made based on milk provocation/restriction and the presence or absence of milk-
specific IgE. Of the seven controls with other allergies, two were allergic to peanuts, two to 
house dust mites and three to birch or grass pollen. 
 
 
IgE- milk allergy IgE+ milk allergy Other allergies Non-atopic 
 
Mean SD Min Max Mean SD Min Max Mean SD Min Max Mean SD Min Max 
Females 5       4       1       2       
Males 2       3       6       1       
Age (y) 1.7 1.4 0.0 4.0 1.7 1.4 0.0 4.0 4.4 1.3 2.0 6.0 6.7 2.3 4.0 8.0 
 
 
 
 
 
 
 
 
 
